RecruitingNCT06764459
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
20 participants
Start Date
Mar 15, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- FLT3 mutated
Exclusion Criteria1
- Respoder to therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06764459
Related Trials
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
NCT069040661 location
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
NCT066976004 locations
IS-free Treg HaploHCT
NCT046784011 location
Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention
NCT066268938 locations